Sex Differences in Mechanisms of Hypertension Associated with Obesity

Sex Differences in Mechanisms of Hypertension Associated with Obesity

November 2, 2019 0 By Jose Scott


(slow techno music) (gears turning) – Hi, I’m Dr. John
Bisognano, the Vice Chair of the AHA Council on high blood pressure. I’m here today with
Dr. Belin de Chantemele from the Medical College of Georgia who just gave a very
impressive presentation at one of our sessions. Very nice to have you here today
and I’d like you to tell us a little bit about what
you presented this morning. – Okay, well thank you very
much for having me here today. This morning I presented
one of our studies looking at the mechanism whereby
obesity leads to hypertension in men and women. We are
interested in sex differences and we are interested in
the role of an adipokine that is contributing to
hypertension called leptin. And what we observe is that
when men and women are obese, leptin level are increased. And what we demonstrate
that those leptin level leads to hypertension via
sex specific mechanism. What we show is that leptin elevates sympathetic nervous system in male. When we saw that leptin
stimulates the production of aldosterone in the female mice, and that those high
aldosterone level leads to endothelial dysfunction and contributes to the development of hypertension
in our obese female mice. Then we are proposing the
new concept that obesity leads to hypertension via
sex specific mechanism. – That’s a very interesting finding. How do you think this will
affect hypertension treatment? I know there’s many steps
between here and there, but how do you think this
will affect hypertension, the evaluation and
treatment in the future? – We propose that we
might want to treat women with inhibitor of the
mineralocorticoid receptor that blocks the action of aldosterone. I think that this approach
will be more affective at reducing blood pressure in obese women. In fact, there is
already a study published a couple of years ago by
the group of George Bakris showing that in fact in
resistant hypertension spironolactone decreases blood
pressure more effectively in women compared to men. We think that our data in mice
further support this evidence and suggests that probably in
terms of personalized medicine we should then treat
women with spironolactone or mineralocorticoid receptor blocker. When in men we should use probably the treatment currently in use. – That’s very interesting
and it really highlights a specific difference in how
we may treat women versus men with high blood pressure in the future. What future directs do you
see this research going in? – Well, one thing that
we want to investigate is what is the affect
of aging and menopause on obesity induced hypertension because so far all the
studies that we have done have been done in young
mice but the question is also what is happening with aging and (mumbles) menopause
because the obese population is aging and we expect that
we probably have different mechanism in older, obese women. – This is very exciting and
I appreciate you spending a little time with us here
today to discuss your research and how it may affect the treatment of high blood pressure in the future. – Well thank you very much
for having me and thank you for the opportunity to present our data also at this meeting. Thank you very much. (slow techno music)